Chief Development Officer, Rockwell Medical Inc., 30142 S Wixom Rd. Wixom, MI 48393, USA
Research Article
Pharmacokinetics and Pharmacodynamics of Unfractionated Heparin and Ferric Pyrophosphate Citrate Co-administration during Hemodialysis: No DrugDrug Interaction
Author(s): Raymond D Pratt*
Background: Ferric Pyrophosphate Citrate (FPC) for intravenous administration is approved to maintain
hemoglobin in patients receiving Chronic Hemodialysis (HD). The aim of this study is to investigate the coadministration
of intravenous (IV) FPC with Unfractionated Heparin (UFH) as an admixture via the HD-machine
syringe pump.
Methods: Open-label, randomized, 3-period crossover study. Three (3) treatments in randomized sequence:
Treatment A: FPC 6.75 mg IV via the post dialyzer blood line and continuous infusion of UFH pre-dialyzer via the
HD-machine infusion pump; Treatment B: FPC 6.75 mg IV mixed with UFH via the pre dialyzer heparin line;
Treatment C; IV UFH via the on machine syringe pump x 3 h. anti-Xa activity, activated prothrombin time (aPTT),
Thrombin time (TT) and serum iron parameters were measured. Pharmacokin.. View more»